Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Serious disease focused PureTech Health said the first participant had been dosed in a clinical study of a treatment for lymphoedema and other fibrotic conditions.
PureTech Health said there was currently not FDA-approved drugs to treat lymphoedema, a painful and chronic condition affecting around 1mindividuals in the US alone, including breast cancer survivors.
The Phase 1 study for the treatment, dubbed LYT-100, would evaluate its safety, tolerability and pharmacokinetic profile in healthy participants.
It was a follow-up to a single ascending dose clinical trial of LYT-100 in healthy individuals that was conducted by Auspex.
Results were expected this year and would enable the initiation of a proof-of-concept study in people with breast cancer-related, upper limb secondary lymphoedema later in 2020.